Table 4

Demographic and clinical exposures across fibrosis stages

F0–F1 (n=114; 95%)F2 (n=4; 3.3%)F3 (n=2; 1.7%)P value *
SexNANANA0.97
 Female62 (54.4)2 (50)1 (50)NA
 Male52 (45.6)2 (50)1 (50)NA
Parental educationNANANA0.43
 Lower than college9 (7.9)1 (25)0NA
 College education105 (92.1)3 (75)2 (100)NA
ResidencyNANANA0.7
 Rural30 (26.3)1 (25)0NA
 Urban84 (73.7)3 (75)2 (100)NA
SmokerNANANA0.37
 Yes8 (7)1 (25)0NA
 No106 (93)3 (75)2 (100)NA
Controlled attenuation parameter (dB/m)211 (198–258)229.5 (197–316.5)268.5 (225–312)0.2
BMI, kg/m224.6 (19.7–30.5)27.1 (22.7–31.9)28.3 (27.2–29.4)0.22
 Underweight (<20 kg/m2)30 (26.3)1 (25)00.7
 Normal weight (20 to <25 kg/m2)30 (26.3)000.34
 Overweight (25 to <30 kg/m2)24 (21.1)2 (50)2 (100)0.014
 Obese (≥30 kg/m2)30 (26.3)1 (25)00.7
Waist-to-height ratio0.48 (0.44–0.55)0.49 (0.46–0.57)0.54 (0.49–0.58)0.31
First-degree history of diabetesNANANA0.46
 Yes37 (32.5)2 (50)0NA
 No77 (67.5)2 (50)2 (100)NA
Fast food consumptionNANANA0.59
 Yes77 (67.5)3 (75)2 (100)NA
 No37 (32.5)1 (25)0NA
ExerciseNANANA0.048
 Yes37 (32.5)02 (100)NA
 No77 (67.5)4 (100)0NA
Alanine aminotransferase, IU/L15 (12–21)12.5 (10–18)20.5 (16–25)0.85
Aspartate aminotransferase,
IU/L
21 (18–25)20.5 (16.5–25.5)23.5 (23–24)0.88
Total cholesterol, mg/dL165 (150–180)162.5 (147.5–199)162.5 (156–169)0.99
Triglycerides, mg/dL79 (63–102)100.5 (88.5–125)124 (114–134)0.015
LDL-C, mg/dL90.5 (77–105)92.5 (79.5–115.5)84.5 (71–98)0.95
HDL-C, mg/dL55 (49–61)54 (45–63)53 (48–58)0.68
Plasma glucose, mg/dL102 (92–110)104 .5 (98.5–113)101.5 (89–114)0.73
Glycated haemoglobin A1c, %5.1 (5–5.3)4.95 (4.85–5.05)5.1 (5.1–5.1)0.32
Serum creatinine, mg/dL0.97 (0.2)1.06 (0.2)1.11 (0.1)0.45
  • Data are n (%), median (IQR) for non-normally distributed data or mean (SD) for normally distributed data as determined by Shapiro-Wilk test.

  • *Pearson’s χ2 test, Wilcoxon rank-sum test or one-way analysis of variance (ANOVA).

  • BMI, body mass index; HDL-C, High-density lipoprotein; LDL-C, Low-density lipoprotein; NA, not applicable.